Ultragenyx Pharmaceutical Inc. - 8-K Filing
Ultragenyx Pharmaceutical Inc. filed to report results from its May 14, 2026 Annual Meeting of Stockholders where stockholders approved the Third Amended and Restated 2023 Incentive Plan (Third A&R 2023 Plan). The plan allows for up to 14,500,000 shares to be issued in satisfaction of awards. Additionally, Class I directors Emil D. Kakkis, M.D., Ph.D., Shehnaaz Suliman, M.D., and Daniel G. Welch were elected with over 98% approval for each candidate. (Items: 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Offi, 5.07 Submission of Matters to a Vote of Security Holders, 9.01 Financial Statements and Exhibits)
Tickers: $RARE